# CSPC Baike (Shandong) Biopharmaceutical trials: 26 (2026)

ClinicalTrials.gov lists 26 trials with CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. as lead sponsor, 4 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.: 26 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/cspc-baike-shandong-biopharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 26
- Recruiting or not yet: 4
- Read on: November 19, 2026

## Trials

The 25 newest of 26, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 30, 2026 | NCT07560033 | A Comparative Pharmacokinetic Study of CM326 in Healthy Subjects | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Healthy Subjects | 192 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07560033) |
| February 19, 2026 | NCT07420257 | A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of CM326 in Participants With Chronic... | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Chronic Rhinosinusitis With Nasal Polyps | 212 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07420257) |
| January 28, 2026 | NCT07372287 | A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Phase 3 | Recruiting | Moderate to Severe Asthma | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07372287) |
| February 17, 2025 | NCT06830343 | The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Phase 1 | Recruiting | Overweight or Obesity | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06830343) |
| September 19, 2024 | NCT06604624 | Semaglutide in Treatment of Obesity | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Phase 3 | Completed | Weight Management | 462 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06604624) |
| February 14, 2024 | NCT06258148 | A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Phase 3 | Completed | Type 2 Diabetes Mellitus | 465 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06258148) |
| January 31, 2024 | NCT06235086 | A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Phase 3 | Completed | Type 2 Diabetes Mellitus | 632 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06235086) |
| January 26, 2024 | NCT06226090 | A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Phase 2 | Completed | Obesity, Overweight | 314 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06226090) |
| August 18, 2023 | NCT05997576 | A Study of TG103 Injection in Non-diabetic Overweight or Obesity | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Phase 3 | Completed | Overweight or Obesity | 675 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05997576) |
| April 27, 2022 | NCT05348122 | A Study of TG103 Injection in Type 2 Diabetes Subjects | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Phase 2 | Unknown | Type 2 Diabetes Mellitus | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05348122) |
| March 29, 2022 | NCT05299697 | A Study of TG103 Injection in Overweight or Obesity | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Phase 2 | Unknown | Overweight or Obesity | 195 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05299697) |
| October 1, 2021 | NCT05063253 | A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Phase 2 | Unknown | Type 2 Diabetes Mellitus | 208 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05063253) |
| June 29, 2021 | NCT04944602 | Study to Evaluate the Therapeutic Equivalence of SYN008 Versus Xolair® in the Treatment of Patients With Refractory Chronic Spontaneous... | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Phase 3 | Unknown | Chronic Spontaneous Urticaria | 340 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04944602) |
| April 22, 2021 | NCT04855292 | A Study of TG103 Injection in Overweight/Obese Subjects Without Diabetes | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Phase 1 | Completed | Diabetes | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04855292) |
| April 9, 2021 | NCT04839744 | A Comparative Study of TG103 Produced by Two Manufacturing Processes in Chinese Healthy Male Subjects | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy Male Subjects | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04839744) |
| August 5, 2020 | NCT04500886 | Evaluate the Efficacy and Safety of PEG-rhG-CSF in Patients With Hemophagocytic Syndrome | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Not applicable | Unknown | Hemophagocytic Syndrome | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04500886) |
| August 4, 2020 | NCT04497701 | Evaluate the Efficacy and Safety of the Prophylactic Use of PEG-rhG-CSF in Children With Hematological Malignancies | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Not applicable | Unknown | Lymphoma, Leukemia | 139 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04497701) |
| August 4, 2020 | NCT04497688 | Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Not applicable | Unknown | Non Hodgkin's Lymphoma | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04497688) |
| January 23, 2020 | NCT04239001 | Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined... | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Not applicable | Unknown | Advanced Pancreatic Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04239001) |
| March 12, 2019 | NCT03870412 | Evaluation of the Application of PEGylated Recombinant Human Granulocyte Stimulating Factor Injection (PEG-rhG-CSF) in Chemotherapy of... | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Not applicable | Unknown | Elderly Lymphoma Patients | 485 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03870412) |
| February 19, 2019 | NCT03846414 | Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Observational | Unknown | Chemotherapy-induced Neutropenia, Myelosuppression | 1,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03846414) |
| December 17, 2018 | NCT03776604 | PEG-rhG-CSF in Elderly Patients With Small Cell Lung Cancer Receiving Chemotherapy | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Not applicable | Unknown | Small Cell Lung Cancer, PEG-rhG-CSF | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03776604) |
| June 17, 2016 | NCT02805218 | PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Phase 4 | Completed | Lymphoma | 410 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02805218) |
| June 17, 2016 | NCT02805205 | PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent Neutropenia | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Phase 4 | Completed | Breast Cancer | 484 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02805205) |
| June 17, 2016 | NCT02805166 | PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Phase 4 | Completed | Malignant Solid Tumors | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02805166) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 4 |
| Phase 2 | 4 |
| Phase 3 | 7 |
| Phase 4 | 4 |
| Not applicable | 6 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 11 |
| Unknown | 11 |
| Recruiting | 2 |
| Not yet recruiting | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Obesity | 4 |
| Overweight | 4 |
| Diabetes Mellitus, Type 2 | 4 |
| Breast Neoplasms | 2 |
| Lymphoma | 2 |
| Leukemia | 1 |
| Lymphohistiocytosis, Hemophagocytic | 1 |
| Lymphoma, Non-Hodgkin | 1 |
| Small Cell Lung Carcinoma | 1 |
| Diabetes Mellitus | 1 |
| Chronic Urticaria | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Hepatology practices in the United States](https://specstream.ai/data/businesses/hepatology-practices/united-states)
- [Spices wholesalers in the United States](https://specstream.ai/data/businesses/spices-wholesalers/united-states)
- [Criminal defense law firms in the United States](https://specstream.ai/data/businesses/criminal-defense-law-firms/united-states)
- [Osteopathic practices in the United States](https://specstream.ai/data/businesses/osteopathic-practices/united-states)
- [B2B cleaning and waste management companies in the United States](https://specstream.ai/data/businesses/b2b-cleaning-and-waste-management-companies/united-states)
- [Hot dog restaurants in the United States](https://specstream.ai/data/businesses/hot-dog-restaurants/united-states)
